Literature DB >> 16245280

Targeting of pericytes diminishes neovascularization and lymphangiogenesis in prostate cancer.

Ugur Ozerdem1.   

Abstract

BACKGROUND: The walls of capillaries in prostate cancer are composed of endothelial cells, and pericytes. NG2 is a transmembrane proteoglycan on nascent pericytes with a functional role in neovascularization.
METHODS: The anti-angiogenic effect of hydron pellets containing NG2 neutralizing antibody was quantified in intracorneal PC-3 and LNCaP xenografts. TRAMP and TRAMP-C1 tumors grafted in NG2 knockout mice represented intrinsic pericyte targeting. TRAMP and TRAMP-C1 grafts were analyzed with confocal microscope for microvascular density (MVD) and lymphatic vascular density (LVD).
RESULTS: NG2 neutralizing antibody decreased corneal neovascularization in PC3 (P<0.0001), and LNCaP (P=0.0079) xenografts. Mean MVD in TRAMP and TRAMP-C1 tumors in NG2 knockout mice were 71% (P=0.0006) and 63% (P=0.0011) lower than wild type controls, respectively. Mean LVD in TRAMP and TRAMP-C1 tumors in NG2 knockout mice were 73% (P=0.0003) and 84% (P<0.0001) lower than wild type controls, respectively.
CONCLUSIONS: Targeting of pericyte-NG2 decreases neovascularization and lymphangiogenesis in prostate cancer significantly. Copyright (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16245280     DOI: 10.1002/pros.20346

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  21 in total

Review 1.  Pericyte dynamics during angiogenesis: new insights from new identities.

Authors:  Peter C Stapor; Richard S Sweat; Derek C Dashti; Aline M Betancourt; Walter Lee Murfee
Journal:  J Vasc Res       Date:  2014-05-17       Impact factor: 1.934

2.  Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway.

Authors:  Vesselina G Cooke; Valerie S LeBleu; Doruk Keskin; Zainab Khan; Joyce T O'Connell; Yingqi Teng; Michael B Duncan; Liang Xie; Genta Maeda; Sylvia Vong; Hikaru Sugimoto; Rafael M Rocha; Aline Damascena; Ricardo R Brentani; Raghu Kalluri
Journal:  Cancer Cell       Date:  2012-01-17       Impact factor: 31.743

3.  Pericyte deficiencies lead to aberrant tumor vascularizaton in the brain of the NG2 null mouse.

Authors:  Feng-Ju Huang; Weon-Kyoo You; Paolo Bonaldo; Thomas N Seyfried; Elena B Pasquale; William B Stallcup
Journal:  Dev Biol       Date:  2010-06-27       Impact factor: 3.582

Review 4.  Understanding angiogenesis during aging: opportunities for discoveries and new models.

Authors:  Nicholas A Hodges; Ariana D Suarez-Martinez; Walter L Murfee
Journal:  J Appl Physiol (1985)       Date:  2018-04-12

5.  Targeting pericytes diminishes neovascularization in orthotopic uveal melanoma in nerve/glial antigen 2 proteoglycan knockout mouse.

Authors:  Ugur Ozerdem
Journal:  Ophthalmic Res       Date:  2006-07-28       Impact factor: 2.892

Review 6.  Antithetic roles of proteoglycans in cancer.

Authors:  Elena Garusi; Silvia Rossi; Roberto Perris
Journal:  Cell Mol Life Sci       Date:  2011-10-02       Impact factor: 9.261

7.  The PCa Tumor Microenvironment.

Authors:  Joseph L Sottnik; Jian Zhang; Jill A Macoska; Evan T Keller
Journal:  Cancer Microenviron       Date:  2011-07-05

Review 8.  Recruitment and retention: factors that affect pericyte migration.

Authors:  Kristina Y Aguilera; Rolf A Brekken
Journal:  Cell Mol Life Sci       Date:  2013-08-04       Impact factor: 9.261

9.  Multivalent proteoglycan modulation of FGF mitogenic responses in perivascular cells.

Authors:  Sabrina Cattaruzza; Ugur Ozerdem; Martin Denzel; Barbara Ranscht; Pietro Bulian; Ugo Cavallaro; Daniela Zanocco; Alfonso Colombatti; William B Stallcup; Roberto Perris
Journal:  Angiogenesis       Date:  2012-11-04       Impact factor: 9.596

10.  Myeloid cells contribute to tumor lymphangiogenesis.

Authors:  Adrian Zumsteg; Vanessa Baeriswyl; Natsuko Imaizumi; Reto Schwendener; Curzio Rüegg; Gerhard Christofori
Journal:  PLoS One       Date:  2009-09-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.